American Journal of Cardiology
Volume 105, Issue 1 , Pages 10-16 , 1 January 2010

Impact of Left Ventricular Ejection Fraction on Clinical Outcomes Over Five Years After Infarct-Related Coronary Artery Recanalization (from the Occluded Artery Trial [OAT])

  • Mariusz Kruk, MD

      Affiliations

    • Institute of Cardiology, Warsaw, Poland
    • ,
  • Christopher E. Buller, MD

      Affiliations

    • Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • James Enlou Tcheng, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University, Durham, North Carolina
    • ,
  • Vladimir Dzavík, MD

      Affiliations

    • Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
    • ,
  • Venugopal Menon, MD

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • ,
  • G.B. John Mancini, MD

      Affiliations

    • Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • Sandra A. Forman, MA

      Affiliations

    • Maryland Medical Research Institute, Baltimore, Maryland
    • ,
  • Peter Kurray, MD

      Affiliations

    • Middle Slovak Institute of Cardiovascular Diseases, Banska Bystrica, Slovakia
    • ,
  • Benita Busz-Papiez, MD

      Affiliations

    • SP Wojewodzki Szpital Zespolony w Szczecinie, Szezecin, Poland
    • ,
  • Gervasio A. Lamas, MD

      Affiliations

    • Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami, Florida
    • ,
  • Judith S. Hochman, MD

      Affiliations

    • New York University School of Medicine, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: (212) 263-6927; fax: 212-263-7129

Received 15 June 2009 ,Revised 4 August 2009 ,Accepted 4 August 2009.

References 

  1. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51
  2. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery (Survival data). Circulation. 1983;68:939–950
  3. Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol. 2005;46:567–574
  4. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–2407
  5. Dzavik V, Buller CE, Lamas GA, Rankin JM, Mancini GB, Cantor WJ, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation. 2006;114(23):2449–2457
  6. Hochman JS, Lamas GA, Knatterud GL, Buller CE, Džavík V, Mark DB, et al. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J. 2005;150:627–642
  7. Konstam MA, Dracup K, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, et al. Heart failure: management of patients with left-ventricular systolic dysfunction. National Library of Medicine DOCLINE information: MED/94282113 1994;
  8. Kruk M, Kadziela J, Sadowski ZP, Barton BA, Mark DB, Forman SA, et al. Predictors of outcome and the lack of effect of PCI across the risk strata in patients with persistent total occlusion after myocardial infarction: results from the Occluded Artery Trial (OAT). JACC Cardiovasc Interv. 2008;1:511–520
  9. Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Teresinska A, Bychowiec B, et al. The occluded artery trial (OAT) viability ancillary study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after PCI vs (medical therapy alone). Circulation. 2007;116:624–625
  10. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6–12
  11. Bounous EP, Mark DB, Pollock BG, Hlatky MA, Harrell FE, Lee KL, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation. 1988;78:I151–I157
  12. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–1158
  13. Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2007;134:1540–1547
  14. Shah PK. Distal embolization after percutaneous coronary interventions: prediction, prevention, and relevance. J Am Coll Cardiol. 2007;50:1647–1648
  15. Jorapur V, Steigen TK, Buller CE, Dzavik V, Webb JG, Strauss BH, et al. Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries post-myocardial infarction: A report form the occluded artery trial. Catheter Cardiovasc Interv. 2008;72:783–789
  16. Malek LA, Reynolds HR, Vozzi C, Dziarmaga M, French JK, Mancini GB, et al. Late coronary intervention in stable patients after myocardial infarction for totally occluded LADs does not reduce events compared to medical therapy alone: results from the Occluded Artery Trial (OAT). Eur Heart J. 2008;29(Abstract Suppl):514–515
  17. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction (Results of the Survival and Ventricular Enlargement trial). Circulation. 1994;90:1731–1738
  18. The CONSENSUS Trial Study Groupt. Effects of enalapril on mortality in severe congestive heart failure (Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)). N Engl J Med. 1987;316:1429–1435
  19. Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. Clin Cardiol. 1999;22(Suppl 5):V30
  20. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  21. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  22. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007;297:1985–1991
  23. Horie H, Takahashi M, Minai K, Izumi M, Takaoka A, Nozawa M, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998;98:2377–2382
  24. Steg PG, Thuaire C, Himbert D, Carrie D, Champagne S, Coisne D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187–2194
  25. Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol. 2002;40:869–876
  26. Dzavik V, Beanlands DS, Davies RF, Leddy D, Marquis JF, Teo KK, et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]—a pilot study). Am J Cardiol. 1994;73:856–861

 This work was supported by grants U01 HL062509 and U01 HL062511 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. Supplemental grant funds and product donations equivalent to 6% of the total study cost were provided by Eli Lilly (Indianapolis, Indiana), Millennium Pharmaceuticals (Cambridge, Massachusetts) and Schering Plough (Kenilworth, New Jersey), Guidant (Indianapolis, Indiana), Cordis/Johnson & Johnson (Bridgewater, New Jersey), Medtronic (Minneapolis, Minnesota), Merck (Whitehouse Station, New Jersey), and Bristol Myers Squibb Medical Imaging (New York, New York).

 The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

 Dr. Hochman received grant support to her institution from Eli Lilly (Indianapolis, Indiana) and Bristol Myers Squibb Medical Imaging (New York, New York) and product donation from Millennium Pharmaceuticals (Cambridge, Massachusetts), Schering Plough (Kenilworth, New Jersey), Guidant (Indianapolis, Indiana), and Merck (Whitehouse Station, NJ) for OAT and received consultation fees from Bristol Myers Squibb (New York, New York), honoraria for Steering Committee service from CV Therapeutics (Palo Alto, California), Eli Lilly (Indianapolis, Indiana), and GlaxoSmithKline (Brentford, London, United Kingdom), and honoraria for serving on the Data Safety Monitoring Board of a trial supported by Schering Plough (Kenilworth, New Jersey). Dr. Mancini received a research grant from Cordis (Bridgewater, New Jersey) and honoraria of <$10,000/yr from Pfizer (New York, New York), Merck Frosst Canada (Kirkland, Quebec, Canada), AstraZeneca (London, United Kingdom), GSK (Brentford, London, United Kingdom), and Sanofi Aventis (Paris, France). Dr. Dzavík reports research, honorarium, and Advisory Board member funds from Cordis, Johnson & Johnson (Bridgewater, New Jersey), and honoraria from Boston Scientific (Natick, Massachusetts).

PII: S0002-9149(09)02209-7

doi: 10.1016/j.amjcard.2009.08.644

American Journal of Cardiology
Volume 105, Issue 1 , Pages 10-16 , 1 January 2010

Article Tools

* Image Usage & Resolution